Annovis Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANVS research report →
Range $21 – $30
Price Chart
About the company
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
- CEO
- Maria L. Maccecchini
- IPO
- 2020
- Employees
- 7
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on ANVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $76.15M
- P/E
- -0.99
- Fwd P/E
- 2.82
- PEG
- 0.57
- P/S
- 0.00
- P/B
- -15.78
- EV/EBITDA
- -1.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -685.96%
- ROIC
- -400.40%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-29,695,258
- Net Income
- $-28,854,197-17.3%
- EPS
- $-1.40+99.9%
- OCF Growth
- -17.0%
- FCF Growth
- -17.0%
- 52W High
- $5.50
- 52W Low
- $1.54
- 50D MA
- $1.79
- 200D MA
- $2.49
- Beta
- 1.24
- RSI (14)
- 49
- Avg Volume
- 902.68K
No earnings-call transcripts are available for ANVS yet.
- Free Float
- 88.9%
- Shares Outstanding
- 42.54M
- Float Shares
- 37.81M
of shares held by institutions
62 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Empery Asset Management, LP | 2.40M | ▲ 2.40M |
| Marshall Wace, Llp | 1.84M | ▲ 654.84K |
| Vanguard Capital Management LLC | 1.65M | ▲ 774.94K |
| Tudor Investment Corp Et Al | 1.36M | ▲ 1.36M |
| Renaissance Technologies LLC | 1.00M | ▲ 654.60K |
| Vanguard Group Inc | 923.20K | ▲ 185.20K |
| Two Sigma Investments, LP | 579.57K | ▼ 48.09K |
| Geode Capital Management, LLC | 283.82K | ▲ 36.30K |
| Blackrock, Inc. | 249.86K | ▲ 110.32K |
| Citadel Advisors LLC | 243.68K | ▲ 243.68K |
| Vanguard Fiduciary Trust Co | 177.53K | ▲ 45.49K |
| Susquehanna International Group, Llp | 146.80K | ▼ 71.53K |
Held by 23 ETFs
Biggest fund positions in ANVS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | Hoffman Michael B | buy | 54,933 |
| May 20, 26 | Hoffman Michael B | buy | 18,849 |
| May 20, 26 | Hoffman Michael B | buy | 2,562 |
| Apr 2, 26 | Hoffman Michael B | buy | 713,800 |
| Dec 8, 25 | Hoffman Michael B | buy | 15,000 |
| Dec 8, 25 | Hoffman Michael B | buy | 30,000 |
| Nov 24, 25 | Hoffman Michael B | buy | 28,096 |
| Nov 24, 25 | Hoffman Michael B | buy | 415 |
| Nov 24, 25 | Hoffman Michael B | buy | 9,200 |
| Nov 24, 25 | Hoffman Michael B | buy | 1,489 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANVS coverage
Recent articles, reports, and earnings notes.
No research on ANVS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANVS report →Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
globenewswire.com · Aug 14
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease
globenewswire.com · Jul 7
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
globenewswire.com · Jul 1
Annovis Bio Regains NYSE Listing Compliance
globenewswire.com · May 26
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
globenewswire.com · May 20
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
globenewswire.com · May 19
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
globenewswire.com · May 15
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
globenewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.